Hims & Hers Health (NYSE:HIMS) Stock Price Breaks Above Fifty Day Moving Average – What’s Next?

Hims & Hers Health, Inc. (NYSE:HIMS) crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $29.15 and traded as high as $29.81. Hims & Hers Health shares last traded at $29.3610, with a volume of 12,251,814 shares changing hands.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: U.S. Department of Health and Human Services reportedly used “enforcement discretion” to temporarily allow compounding of six peptides. The policy could improve Hims & Hers’ access to compounded treatments and support growth, although its temporary nature creates continuing uncertainty. Hims & Hers Jumped as HHS Uses Enforcement Discretion to Open Peptide Compounding
• Positive Sentiment: Earlier strength in telehealth stocks following Teladoc’s better-than-expected results provided some support for Hims & Hers and highlighted continued investor interest in digital-health companies. Teladoc Soars as Revenue and Profit Beat Estimates
• Neutral Sentiment: Insider Soleil Boughton sold 3,462 shares for approximately $95,551 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s position by about 1.16% and is therefore a limited signal about management’s outlook. SEC Insider Trading Filing
• Negative Sentiment: Multiple law firms are soliciting investors ahead of the November 2, 2026 deadline to seek lead-plaintiff status in a federal securities class action covering purchases from August 4, 2025, through July 29, 2026. The litigation stems in part from allegations associated with an FTC complaint and could expose Hims & Hers to legal expenses, potential damages, reputational harm and further scrutiny. The repeated notices appear to be the primary near-term catalyst weighing on the stock. HIMS Securities Class Action Deadline Alert

Analyst Ratings Changes

A number of research analysts have recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Weiss Ratings restated a “sell (d)” rating on shares of Hims & Hers Health in a research note on Friday, August 7th. Citigroup dropped their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, August 11th. Finally, Morgan Stanley increased their target price on shares of Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $32.43.

Hims & Hers Health Stock Performance

The business’s fifty day moving average price is $29.04 and its 200-day moving average price is $27.08. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The stock has a market capitalization of $6.44 billion, a PE ratio of -43.79 and a beta of 2.44.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s revenue was up 38.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.17 EPS. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.

Insider Activity at Hims & Hers Health

In other news, insider Soleil Boughton sold 25,111 shares of Hims & Hers Health stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total transaction of $691,808.05. Following the sale, the insider owned 313,964 shares of the company’s stock, valued at approximately $8,649,708.20. The trade was a 7.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $28.39, for a total value of $398,226.53. Following the sale, the chief operating officer directly owned 456,660 shares in the company, valued at approximately $12,964,577.40. The trade was a 2.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 133,905 shares of company stock valued at $3,826,977 in the last 90 days. 11.76% of the stock is owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently bought and sold shares of the business. Greenfield Seitz Capital Management LLC raised its holdings in shares of Hims & Hers Health by 4.6% during the third quarter. Greenfield Seitz Capital Management LLC now owns 385,366 shares of the company’s stock valued at $11,480,000 after purchasing an additional 17,027 shares during the last quarter. Kurv Investment Management LLC grew its position in Hims & Hers Health by 25.9% in the 3rd quarter. Kurv Investment Management LLC now owns 65,274 shares of the company’s stock worth $1,945,000 after purchasing an additional 13,409 shares during the period. Prosperitas Financial LLC purchased a new stake in Hims & Hers Health during the 3rd quarter valued at $2,649,000. VestGen Advisors LLC raised its stake in Hims & Hers Health by 256.4% during the 3rd quarter. VestGen Advisors LLC now owns 20,578 shares of the company’s stock valued at $613,000 after buying an additional 14,804 shares during the last quarter. Finally, Evergreen Capital Management LLC purchased a new stake in Hims & Hers Health during the 3rd quarter valued at $446,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.